Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Ischemic Heart Disease

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    December 2025
  1. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
    TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
    Lancet. 2025;404:2593-2602.
    PubMed     Abstract available


  2. TARANTINI G, Cardaioli F
    TAVI and PCI: redefining treatment for aortic stenosis and complex coronary artery disease.
    Lancet. 2025;404:2492-2493.
    PubMed    


    June 2025
  3. CONRAD N, Rahimi K, McMurray JJV, Casadei B, et al
    The changing spectrum of cardiovascular diseases.
    Lancet. 2025 Jun 9:S0140-6736(25)00990-0. doi: 10.1016/S0140-6736(25)00990.
    PubMed    


  4. THE LANCET
    From innovation to impact in cardiovascular disease.
    Lancet. 2025;405:2023.
    PubMed    


    May 2025
  5. LEE SJ, Kim BK
    Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease.
    Lancet. 2025 May 5:S0140-6736(25)00827-X. doi: 10.1016/S0140-6736(25)00827.
    PubMed    


    April 2025
  6. HUANG C
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1463.
    PubMed    


  7. VALGIMIGLI M, Hong SJ, Gragnano F, Hong MK, et al
    Ticagrelor monotherapy for acute coronary syndromes - Authors' reply.
    Lancet. 2025;405:1463-1464.
    PubMed    


  8. APOSTOLOS A, Tsigkas G
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1462-1463.
    PubMed    


  9. GUO C, Shan D, Liu Z, He F, et al
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1461-1462.
    PubMed    


  10. ONIDA S, Davies AH
    Cardiovascular risk assessment in venous disease?
    Lancet. 2025;405:1141-1142.
    PubMed    


    March 2025
  11. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    PubMed     Abstract available


  12. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    PubMed     Abstract available


  13. HU X, Zhang J, Yang S, Jiang J, et al
    Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504.
    PubMed     Abstract available


  14. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    PubMed     Abstract available


  15. TAM DY, Lee G, Chikwe J
    Fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting: please mind the gap.
    Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583.
    PubMed    


  16. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    PubMed    


  17. ROSSELLO X, Kristensen AMD
    Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice.
    Lancet. 2025 Mar 28:S0140-6736(25)00562-8. doi: 10.1016/S0140-6736(25)00562.
    PubMed    


  18. ZAMAN S, Wasfy JH, Kapil V, Ziaeian B, et al
    The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
    Lancet. 2025 Mar 25:S0140-6736(25)00055-8. doi: 10.1016/S0140-6736(25)00055.
    PubMed    


  19. THE LANCET
    Rethinking coronary artery disease: a call to action.
    Lancet. 2025 Mar 25:S0140-6736(25)00497-0. doi: 10.1016/S0140-6736(25)00497.
    PubMed    


  20. CHANDRASHEKHAR Y, Mensah G, Narula J
    From coronary artery disease to atherosclerotic coronary artery disease: what is in a name?
    Lancet. 2025 Mar 25:S0140-6736(25)00563-X. doi: 10.1016/S0140-6736(25)00563.
    PubMed    


  21. WILSON C
    Nancy Brown: using advocacy to advance cardiovascular health.
    Lancet. 2025;405:688.
    PubMed    


    February 2025
  22. XU C
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:545.
    PubMed    


  23. CHAN K, Neubauer S, Channon KM, Deanfield J, et al
    Inflammatory cardiovascular events and coronary artery disease - Authors' reply.
    Lancet. 2025;405:545-546.
    PubMed    


  24. ZHAO K, Chen L, Sun Z
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544.
    PubMed    


  25. NURMOHAMED NS, Beverloo CYY, Kraaijenhof JM, Stroes ESG, et al
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544-545.
    PubMed    


    January 2025
  26. WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al
    Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
    Lancet. 2025;405:329-337.
    PubMed     Abstract available


    November 2024
  27. LUSEBRINK E, Binzenhofer L, Adamo M, Lorusso R, et al
    Cardiogenic shock.
    Lancet. 2024;404:2006-2020.
    PubMed     Abstract available


    October 2024
  28. ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al
    Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
    Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175.
    PubMed     Abstract available


  29. BECKER LM, Swaans MJ
    Present and future of functional measurements in coronary revascularisation.
    Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367.
    PubMed    


  30. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
    Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227.
    PubMed     Abstract available


  31. CAPODANNO D
    Coronary stenting with bioadaptors.
    Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359.
    PubMed    


    September 2024
  32. THIELE H, Moller JE, Henriques JPS, Bogerd M, et al
    Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
    Lancet. 2024;404:1019-1028.
    PubMed     Abstract available


  33. NORDESTGAARD BG, Langsted A
    Lipoprotein(a) and cardiovascular disease.
    Lancet. 2024 Sep 12:S0140-6736(24)01308-4. doi: 10.1016/S0140-6736(24)01308.
    PubMed     Abstract available


    August 2024
  34. KRUMHOLZ HM, Geraldes F, Wilson C, Horton R, et al
    The Lancet-JACC collaboration: advancing cardiovascular health.
    Lancet. 2024;404:833-834.
    PubMed    


  35. JENTZER JC, Hibbert B
    Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock.
    Lancet. 2024 Aug 30:S0140-6736(24)01588-5. doi: 10.1016/S0140-6736(24)01588.
    PubMed    


  36. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    PubMed     Abstract available


  37. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    PubMed    


  38. GAO C, He X, Ouyang F, Zhang Z, et al
    Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
    Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594.
    PubMed     Abstract available


  39. MCENTEGART MB, Kirtane AJ
    How feasible is a cage-free solution for de novo coronary artery disease?
    Lancet. 2024 Aug 30:S0140-6736(24)01696-9. doi: 10.1016/S0140-6736(24)01696.
    PubMed    


  40. VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al
    De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
    Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616.
    PubMed     Abstract available


  41. STEFANINI GG, Oliva A
    Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?
    Lancet. 2024 Aug 30:S0140-6736(24)01678-7. doi: 10.1016/S0140-6736(24)01678.
    PubMed    


  42. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available


    June 2024
  43. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    PubMed     Abstract available


  44. GAO Y, Li Z, Liu M, Tian J, et al
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    PubMed    


  45. YU Z, Li G
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    PubMed    


  46. ZEYMER U, Freund A, Hochadel M, Schneider S, et al
    VA-ECMO for infarct-related cardiogenic shock - Authors' reply.
    Lancet. 2024;403:2487-2488.
    PubMed    


  47. LI Y
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    PubMed    


  48. DALZELL JR
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    PubMed    


  49. WANG G, Guan J, Liu Z
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2485.
    PubMed    


  50. KELLY P, Lemmens R, Weimar C, Walsh C, et al
    Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
    PubMed     Abstract available


    May 2024
  51. CHAN K, Wahome E, Tsiachristas A, Antonopoulos AS, et al
    Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.
    Lancet. 2024 May 29:S0140-6736(24)00596-8. doi: 10.1016/S0140-6736(24)00596.
    PubMed     Abstract available


  52. COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al
    Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
    Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921.
    PubMed     Abstract available


    April 2024
  53. FOLEY MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, et al
    Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
    Lancet. 2024;403:1543-1553.
    PubMed     Abstract available


  54. MONTI CB, Palmisano A
    Coronary sinus reducer: a new hope for refractory angina?
    Lancet. 2024;403:1514-1515.
    PubMed    


  55. LI X, Ge Z, Kan J, Anjum M, et al
    Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
    PubMed     Abstract available


  56. DEN DEKKER WK
    Is intravascular imaging the future of percutaneous coronary intervention?
    Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
    PubMed    


  57. GE Z, Kan J, Gao X, Raza A, et al
    Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
    PubMed     Abstract available


  58. STEINER-GAGER GM, Siller-Matula JM
    Abbreviated dual antiplatelet therapy after acute coronary syndrome.
    Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586.
    PubMed    


  59. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
    Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
    PubMed     Abstract available


  60. BOROVAC JA
    Percutaneous coronary intervention for non-obstructive vulnerable plaques.
    Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
    PubMed    


    March 2024
  61. RIDKER PM, Bhatt DL, Nissen SE
    Inflammation, infection, and cardiovascular risk - Authors' reply.
    Lancet. 2024;403:1025-1026.
    PubMed    


  62. SHARMA S, Sharma R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1024-1025.
    PubMed    


  63. GOLDMAN M, Bondue A, Cogan E
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023.
    PubMed    


  64. GOLDSTEIN MR, Mascitelli L
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023-1024.
    PubMed    


  65. DROZD M, Cubbon R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022-1023.
    PubMed    


  66. PAREEK A, Chandurkar N, Naidu K, Raut V, et al
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022.
    PubMed    


  67. STRANDBERG TE, Kovanen PT, Gylling H
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021.
    PubMed    


  68. LIN GM, Huang WC, Han CL
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021-1022.
    PubMed    


    February 2024
  69. LEE ZS, Ryan N
    Intravascular imaging in percutaneous coronary intervention.
    Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
    PubMed    


  70. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.